Boston Scientific (BSX) Tops Q2 EPS by 2c; offers guidance

Boston Scientific (NYSE: BSX) reported Q2 EPS of $0.75, $0.02 better than the analyst estimate of $0.73. Revenue for the quarter came in at $5.06 billion versus the consensus estimate of $4.89 billion.

GUIDANCE:

Boston Scientific sees FY2025 EPS of $2.95-$2.99, versus the consensus of $2.92.

Boston Scientific sees Q3 2025 EPS of $0.70-$0.72, versus the consensus of $0.70.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.

You May Also Be Interested In

• RBC Capital Upgrades Healius Limited (HLS:AU) (PHCRF) to Sector Perform
• HSBC Upgrades TotalEnergies SE (TTE:FP) (TTE) to Buy
• UBS Starts Chemed (CHE) at Buy